Company intelligence / Profile preview

Immucura

Marbella, Andalusia, Spainimmucura.com ↗

Ownership: Private
Development stage: Commercial

Overview

Immucura provides non-invasive alternative cancer therapies centered on dendritic cell immunotherapy and comprehensive diagnostic packages. Their approach includes personalized blood analyses (>250 markers), liquid biopsies for early detection of over 70 solid tumor types, proteome analysis for immune/metabolic markers, nutritional support plans tailored to individual needs, and a holistic support package. There are no published clinical trial results or peer-reviewed efficacy data available from the company itself.

Therapeutic areas: Oncology
Modalities: Dendritic cell therapy (Dendritic cell immunotherapy)Autologous cell therapy (using patient-derived immune cells)Diagnostic tests (liquid biopsy, proteome analysis)Nutritional and supplement-based interventions
Industry: Biotech

Beyond the preview

Go deeper on Immucura.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immucura.